Drug ID:Drug186
Drug Name:MS-20
CID:146651362
DrugBank ID:NULL
Modality:Small Molecule
Groups:NULL
US Approved:NULL
Other Approved:NULL
Identifier: NCT04908644
Molecular Formula:C24H21N3O3
Molecular Weight:399.4 g/mol
Isomeric SMILES:CC1=NC(=CC=C1)OC2=CC(=CC(=C2)OC3=CC=CC(=N3)C)OC4=CC=CC(=N4)C
Synonyms:Amelenodor; Amelenodor [INN]; NX-13; NX-13 free base; 2389235-01-0; DVH35H3HDB; UNII-DVH35H3HDB; 1,3,5-Tris((6-methylpyridin-2-yl)oxy)benzene; 2,2',2''-(1,3,5-Benzenetriyltris(oxy))tris(6-methylpyridine; 2,2',2''-(Benzene-1,3,5-triyltris(oxy))tris(6-methylpyridine)
Phase 0: 0
Phase 1: 0
Phase 2: 0
Phase 3: 0
Phase 4: 0
Description:NULL

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt1313 146651362 Amelenodor 79671 NLRX1 Homo sapiens (human) Activation
dt1314 146651362 Amelenodor 79671 NLRX1 Homo sapiens (human) Agonist

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT04908644 MS-20 on Patients With Ulcerative Colitis(UC) None RECRUITING National Taiwan University Hospital Ulcerative Colitis DRUG: MS-20 oral solution|OTHER: Placebo Details
NCT04862741 Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis PHASE1 COMPLETED Landos Biopharma Inc. Ulcerative Colitis DRUG: NX-13 250mg IR|DRUG: NX-13 500mg IR|DRUG: N… Details
NCT04458805 Safety, Tolerability and Pharmacokinetics of Oral NX-13 in Healthy Adults Male and Female Volunteers PHASE1 COMPLETED Landos Biopharma Inc. Ulcerative Colitis DRUG: NX-13 250 mg|DRUG: Placebo Details
NCT05785715 Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis PHASE2 ACTIVE_NOT_RECRUITING AbbVie Ulcerative Colitis DRUG: NX-13 250mg|DRUG: NX-13 750mg|DRUG: NX-13 P… Details
NCT04624230 Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis PHASE3 RECRUITING Pfizer Ulcerative Colitis DRUG: tofacitinib Details
NCT06651281 Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011) PHASE3 RECRUITING Merck Sharp & Dohme LLC Crohn Disease|Colitis, Ulcerative DRUG: Tulisokibart|DRUG: Placebo to tulisokibart Details
NCT04857112 Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis PHASE2 ACTIVE_NOT_RECRUITING Bausch Health Americas, Inc. Ulcerative Colitis DRUG: Low Dose MT-1303|DRUG: High Dose MT-1303|DR… Details
NCT05986136 Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease PHASE2|PHASE3 RECRUITING Mostafa Bahaa Inflammatory Bowel Diseases DRUG: Mesalamine|DRUG: Dapagliflozin 10mg Tab Details
NCT06353828 Phase 2a Study to Evaluate IcBD-01 Enema in Active Ulcerative Colitis Patients PHASE2 ACTIVE_NOT_RECRUITING CannaMore Biotechs Ulcerative Colitis DRUG: CBD, synthetic form|DRUG: Placebo Details
NCT04478825 Efficacy and Safety of Rectally Administered BBT-401-1S in Subjects With Ulcerative Colitis PHASE1 TERMINATED Bridge Biotherapeutics, Inc. Ulcerative Colitis DRUG: BBT-401-1S Details
NCT06570772 Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio PHASE3 RECRUITING Alvotech Swiss AG Ulcerative Colitis BIOLOGICAL: AVT16|BIOLOGICAL: Vedolizumab Details
NCT01290042 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181. PHASE1 COMPLETED Amgen Ulcerative Colitis|Crohn's Disease DRUG: AMG 181|OTHER: Placebo for AMG 181 Details
NCT05507203 ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 PHASE3 RECRUITING Abivax S.A. Ulcerative Colitis DRUG: ABX464|DRUG: Placebo Details
NCT00207688 A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients None COMPLETED Janssen Research & Development, LLC Ulcerative Colitis DRUG: Infliximab 5 mg/kg|DRUG: Infliximab 10 mg/k… Details
NCT04677179 A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) PHASE2 TERMINATED Nektar Therapeutics Colitis, Ulcerative DRUG: LY3471851|DRUG: Placebo Details
NCT02611830 Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis PHASE3 COMPLETED Takeda Colitis, Ulcerative DRUG: Vedolizumab 300 mg IV|DRUG: Placebo IV|DRUG… Details
NCT02958865 Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis PHASE2 COMPLETED Pfizer Ulcerative Colitis DRUG: PF-06651600 or Placebo|DRUG: PF-06700841 or… Details
NCT06420492 Study of Novel Therapeutics for Acute Remedy of Colitis PHASE2 NOT_YET_RECRUITING Brigham and Women's Hospital Ulcerative Colitis|Ulcerative Colitis Chronic Mod… DRUG: BRS201 Details
NCT03943550 Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC) PHASE1 TERMINATED Hoffmann-La Roche Ulcerative Colitis DRUG: RO7049665|DRUG: Placebo Details
NCT04133194 Adherence of a 1.600 mg Single Tablet 5-ASA Treatment of Ulcerative Colitis PHASE4 RECRUITING Flemming Bendtsen Ulcerative Colitis DRUG: Mesalazine|DRUG: Mesalazine Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
S04 T-cell homing and retention T-cell trafficking vedolizumab; anti-MAdCAM1 antibodies ; etrolizumab Inhibition of the interaction between α4β7 integrins on T c… Details
S06 Anti-fibrosis fibrosis; tissue remodelling GS-5745; STNM01 Tissue remodelling and destruction in patients with IBD is … Details
S07 Blockade of cytokine Cytokine signalling apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab Various T-cell subsets, their differentiation pathways and … Details

No related literature

You can run management commands to establish drug-literature associations